Introduction {#tca12995-sec-0005}
============

Lung cancer is the most common and serious type of cancer worldwide.[1](#tca12995-bib-0001){ref-type="ref"}, [2](#tca12995-bib-0002){ref-type="ref"} There are two main types of primary lung cancer, non‐small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).[3](#tca12995-bib-0003){ref-type="ref"}, [4](#tca12995-bib-0004){ref-type="ref"} NSCLC accounts for approximately 85% of all new lung cancer diagnoses.[3](#tca12995-bib-0003){ref-type="ref"} Currently, the clinical treatment decisions and prognostic prediction for NSCLC are based on tumor node metastasis (TNM) staging. However, because of the late and rapid clinical manifestations of occult symptoms of the disease, prognosis is extremely poor.[5](#tca12995-bib-0005){ref-type="ref"} In addition, accurate TNM staging is obtained postoperatively, and preoperative prediction remains difficult. Although molecular profiling has shown great potential to guide patient management strategies, the tools are complex and expensive at present. Therefore, more potential and propagable biomarkers should be included in clinical practice to improve prognostic prediction of NSCLC.

Recently some inflammation‐based parameters, such as the neutrophil‐lymphocyte ratio (NLR) and platelet‐lymphocyte ratio (PLR), have been reported to be associated with patient survival for several types of solid tumors, such as lung,[6](#tca12995-bib-0006){ref-type="ref"}, [7](#tca12995-bib-0007){ref-type="ref"} breast,[8](#tca12995-bib-0008){ref-type="ref"} melanoma,[9](#tca12995-bib-0009){ref-type="ref"} colorectal,[10](#tca12995-bib-0010){ref-type="ref"} gastric,[11](#tca12995-bib-0011){ref-type="ref"} and esophageal.[12](#tca12995-bib-0012){ref-type="ref"} However, these two inflammatory indicators only integrate two types of inflammatory cells. The systemic immune‐inflammation index (SII), a parameter that integrates three types of inflammatory cells (lymphocytes, neutrophils, and platelets), has been shown to be more promising than the NLR or PLR.[13](#tca12995-bib-0013){ref-type="ref"}, [14](#tca12995-bib-0014){ref-type="ref"}, [15](#tca12995-bib-0015){ref-type="ref"}, [16](#tca12995-bib-0016){ref-type="ref"} Three studies have reported the prognostic significance of the SII in NSCLC.[17](#tca12995-bib-0017){ref-type="ref"}, [18](#tca12995-bib-0018){ref-type="ref"}, [19](#tca12995-bib-0019){ref-type="ref"} Although these studies showed that the SII was an independent prognostic predictor for NSCLC patients, their cohorts included a relatively small number of patients. Thus, we conducted the present study to investigate and verify the prognostic value of the SII in a larger cohort of patients with surgically resected NSCLC.

Methods {#tca12995-sec-0006}
=======

Patients {#tca12995-sec-0007}
--------

Medical records of 569 NSCLC patients who underwent curative lobectomy with R0 resection between July 2006 and May 2012 at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College were retrospectively reviewed. The inclusion criteria were: histologically confirmed NSCLC with complete clinical information, laboratory data, and follow‐up. The exclusion criteria were: administration of neoadjuvant chemoradiotherapy; in‐hospital death; and clinical evidence of chronic inflammatory, hematological, or autoimmune diseases. Patients were followed up regularly in the outpatient clinic every three to six months for the first two two years after surgery and then annually thereafter. Follow‐up concluded on 27 September 2018.

The study followed the guidelines of the Helsinki Declaration and was approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Informed consent was exempted for this retrospective study.

Clinicopathological parameters {#tca12995-sec-0008}
------------------------------

Patient clinicopathological parameters, including age, gender, smoking history, pathological diagnosis, tumor differentiation grade, tumor size, lymph node metastasis, TNM stage, operation duration, intraoperative blood loss, and routine blood results, were obtained from medical records. Tumor staging was assessed according to the eighth edition of the American Joint Committee on Cancer TNM staging system.[20](#tca12995-bib-0020){ref-type="ref"}

Blood sample analysis and systemic immune‐inflammation index (SII), neutrophil‐lymphocyte ratio (NLR), and platelet‐lymphocyte ratio (PLR) evaluations {#tca12995-sec-0009}
------------------------------------------------------------------------------------------------------------------------------------------------------

Complete blood count data were analyzed in the general laboratory of our hospital within one week before surgery. We calculated the SII, NLR, and PLR as follows: SII = platelet count × neutrophil count/lymphocyte count, NLR = neutrophil count/lymphocyte count, and PLR = platelet count/lymphocyte count.

Statistical analysis {#tca12995-sec-0010}
--------------------

SPSS version 19.0 (IBM Corp., Armonk, NY, USA) was used to perform all statistical analyses. The Pearson chi‐square test was used to compare categorical variables. Multiple linear regression analyses were used to determine the factors associated with the SII, NLR, and PLR. We constructed receiver operating characteristic (ROC) curves to determine the optional cutoff values for the SII, NLR, and PLR that yielded the maximum joint sensitivity and specificity. The Kaplan--Meier method was used to perform survival analyses, and the differences between the survival curves were compared by the log‐rank test. We used the Cox proportional hazard model for univariate and multivariate analyses, and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to quantify the prognostic value of the predictors. A two‐sided value of *P* \< 0.05 was considered statistically significant.

Results {#tca12995-sec-0011}
=======

Patient characteristics {#tca12995-sec-0012}
-----------------------

The 569 patients included in this study consisted of 425 (74.7%) men and 144 (25.3%) women (Table [1](#tca12995-tbl-0001){ref-type="table"}). The median age was 60 (range: 27--80) years. The distribution of pathological stages was as follows: stage I, 147 patients (25.8%); stage II, 177 patients (31.1%); and stage III, 245 patients (43.1%). The mean follow‐up duration was 60.3 (range: 0.9--146.7) months. At the final follow‐up, 345 (60.6%) patients had died.

###### 

Characteristics of the NSCLC patients grouped by SII values

                                                SII         
  -------------------------------- ------------ ----- ----- ----------------------------------------------------
  Gender                                                    **0.016** [\*](#tca12995-note-0002){ref-type="fn"}
  Male                             425 (74.7)   183   242   
  Female                           144 (25.3)   79    65    
  Age (years)                                               0.401
  ≤ 60                             286(50.3)    137   149   
  \> 60                            283 (49.7)   125   158   
  Smoking                                                   0.377
  Ever                             372 (65.4)   166   206   
  Never                            197 (34.6)   96    101   
  Histological type                                         **0.014** [\*](#tca12995-note-0002){ref-type="fn"}
  LUAD                             295 (51.8)   153   142   
  LUSC                             225 (39.5)   88    137   
  Others                           49 (8.6)     21    28    
  Tumor size                                                **0.001** [\*](#tca12995-note-0002){ref-type="fn"}
  ≤ 4                              277 (48.7)   165   112   
  \> 4                             292 (51.3)   97    195   
  Differentiation                                           0.800
  Well                             182 (32.0)   83    99    
  Moderately                       195 (34.3)   87    108   
  Poorly                           192 (33.7)   92    100   
  T stage                                                   **0.000** [\*](#tca12995-note-0002){ref-type="fn"}
  T1                               144 (25.3)   89    55    
  T2                               284 (49.9)   132   152   
  T3                               107 (18.8)   33    74    
  T4                               34 (6.0)     8     26    
  N stage                                                   0.356
  N0                               223 (39.2)   112   111   
  N1                               142 (25.0)   61    81    
  N2                               201 (35.3)   87    114   
  N3                               3 (0.5)      2     1     
  Lymph node metastasis                                     0.121
  Negative                         223 (39.2)   54    20    
  Positive                         346 (60.8)   86    40    
  TNM stage                                                 **0.001** [\*](#tca12995-note-0002){ref-type="fn"}
  I                                147 (25.8)   87    60    
  II                               177 (31.1)   77    100   
  III                              245 (43.1)   98    147   
  Operation duration (minutes)                              0.933
  \< 150                           302(53.1)    140   162   
  ≥ 150                            267 (46.9)   122   145   
  Intraoperative blood loss (mL)                            
  \< 150                           170 (29.9)   73    97    0.359
  ≥ 150                            399 (70.1)   189   210   
  NLR                                                       **0.001** [\*](#tca12995-note-0002){ref-type="fn"}
  Low                              200 (35.1)   179   21    
  High                             369 (64.9)   83    286   
  PLR                                                       **0.001** [\*](#tca12995-note-0002){ref-type="fn"}
  Low                              144 (25.3)   132   12    
  High                             425 (74.7)   130   295   

*P* \< 0.05 is considered significant. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NLR, neutrophil‐lymphocyte ratio; NSCLC, non‐small cell lung cancer; PLR, platelet‐lymphocyte ratio; SII, systemic immune‐inflammation index; TNM, tumor node metastasis.

At baseline, the median preoperative SII, NLR, and PLR values were 594.7 (range: 66.0--3394.4), 2.47 (range: 0.36--16.65), and 127.5 (range: 32.0--1088.2), respectively.

Selection of optimal cutoff values for the SII, NLR, and PLR {#tca12995-sec-0013}
------------------------------------------------------------

Previous studies have suggested different cutoff values when analyzing the prognostic value of the SII, NLR, and PLR. In the present study, we constructed ROC curves to determine the optional cutoff values. As shown in Figure [1](#tca12995-fig-0001){ref-type="fig"}, the areas under the ROC curves (AUCs) were 0.547, 0.541, and 0.531 for the SII, NLR, and PLR, respectively. The optimal cutoff values for the prediction of survival were 419.6 for the SII, 1.74 for the NLR, and 88.7 for the PLR. Consequently, we separated the patients into two groups according to the optimal cutoff values. Three hundred seven patients (54.0%) had SII values ≥ 419.6, 369 patients (64.8%) had NLRs ≥ 1.74, and 425 patients (73.8%) had PLRs ≥ 88.7.

![Receiver operating characteristic (ROC) curve analysis of the optimal cutoff value of the systemic immune‐inflammation index (SII), neutrophil‐lymphocyte ratio (NLR), and platelet‐lymphocyte ratio (PLR). The areas under the curve for overall survival were 0.547, 0.541, and 0.531 for the SII, NLR, and PLR, respectively. (![](TCA-10-761-g004.jpg "image")) SII, (![](TCA-10-761-g005.jpg "image")) NLR, (![](TCA-10-761-g006.jpg "image")) PLR, and (![](TCA-10-761-g007.jpg "image")) Reference Line.](TCA-10-761-g001){#tca12995-fig-0001}

Correlation between clinicopathological parameters and the SII, NLR, and PLR {#tca12995-sec-0014}
----------------------------------------------------------------------------

Correlations between the clinicopathological parameters and the SII are shown in Table [1](#tca12995-tbl-0001){ref-type="table"}. The preoperative SII was associated with gender (*P* = 0.016), histological type (*P* = 0.014), tumor length (*P* \< 0.001), T stage (*P* \< 0.001), TNM stage (*P* \< 0.001), NLR (*P* \< 0.001), and PLR (*P* \< 0.001). No other significant differences were found between the groups.

Correlations between the clinicopathological parameters and the NLR and PLR are shown in Table [2](#tca12995-tbl-0002){ref-type="table"}. The preoperative NLR was associated with gender (*P* \< 0.001), smoking history (*P* = 0.007), histological type (*P* = 0.009), tumor length (*P* \< 0.001), and T stage (*P* \< 0.001). The preoperative PLR was associated with gender (*P* = 0.001), smoking history (*P* = 0.001), tumor length (*P* \< 0.001), and intraoperative blood loss (*P* = 0.036). No other significant differences were found between the groups.

###### 

Characteristics of the NSCLC patients grouped by NLR and PLR values

                                                NLR         PLR                                                              
  -------------------------------- ------------ ----- ----- ---------------------------------------------------- ----- ----- ----------------------------------------------------
  Gender                                                    **0.001** [\*](#tca12995-note-0003){ref-type="fn"}               **0.001** [\*](#tca12995-note-0003){ref-type="fn"}
  Male                             425 (74.7)   121   304                                                        122   303   
  Female                           144 (25.3)   79    65                                                         22    122   
  Age (years)                                               0.380                                                            0.773
  ≤ 60                             286 (50.3)   106   180                                                        74    212   
  \> 60                            283 (49.7)   94    189                                                        70    213   
  Smoking                                                   **0.007** [\*](#tca12995-note-0003){ref-type="fn"}               **0.001** [\*](#tca12995-note-0003){ref-type="fn"}
  Ever                             372 (46.0)   116   256                                                        111   261   
  Never                            197 (54.0)   84    133                                                        33    164   
  Histological type                                         **0.009** [\*](#tca12995-note-0003){ref-type="fn"}               0.642
  LUAD                             295 (51.8)   121   174                                                        70    225   
  LUSC                             225 (39.5)   64    161                                                        60    165   
  Others                           49 (8.6)     15    34                                                         14    35    
  Tumor length                                              **0.001** [\*](#tca12995-note-0003){ref-type="fn"}               **0.001** [\*](#tca12995-note-0003){ref-type="fn"}
  ≤ 4                              277 (48.7)   124   153                                                        89    188   
  \> 4                             292 (51.3)   76    216                                                        55    237   
  Differentiation                                           0.342                                                            0.913
  Well                             182 (32.0)   57    125                                                        48    134   
  Moderately                       195 (34.3)   69    126                                                        49    146   
  Poorly                           192 (33.7)   74    118                                                        47    145   
  T stage                                                   **0.001** [\*](#tca12995-note-0003){ref-type="fn"}               0.072
  T1                               144 (25.3)   70    74                                                         46    98    
  T2                               284 (49.9)   97    187                                                        68    216   
  T3                               107 (18.8)   27    80                                                         26    81    
  T4                               34 (6.0)     6     34                                                         4     30    
  N stage                                                   0.235                                                            0.249
  N0                               223 (39.2)   82    141                                                        61    162   
  N1                               142 (25.0)   52    90                                                         41    101   
  N2                               201 (35.3)   65    136                                                        41    160   
  N3                               3 (0.5)      1     2                                                          1     2     
  Lymph node metastasis                                     0.530                                                            0.376
  Negative                         223 (39.2)   36    38                                                         61    162   
  Positive                         346 (60.8)   54    72                                                         83    263   
  TNM stage                                                 0.107                                                            0.099
  I                                147 (25.8)   60    87                                                         43    104   
  II                               177 (31.1)   65    112                                                        50    127   
  III                              245 (43.1)   75    170                                                        51    194   
  Operation duration (minutes)                              0.187                                                            0.334
  \< 150                           302(53.1)    114   118                                                        71    231   
  ≥ 150                            267 (46.9)   86    181                                                        72    194   
  Intraoperative blood loss (mL)                            0.848                                                            **0.036** [\*](#tca12995-note-0003){ref-type="fn"}
  \< 150                           170 (29.9)   61    109                                                        33    137   
  ≥ 150                            399 (70.1)   139   260                                                        111   288   

*P* \< 0.05 is considered significant. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NLR, neutrophil‐lymphocyte ratio; NSCLC, non‐small cell lung cancer; PLR, platelet‐lymphocyte ratio; TNM, tumor node metastasis.

Prognostic values of the SII, NLR, and PLR {#tca12995-sec-0015}
------------------------------------------

We used the Kaplan--Meier method to plot the overall survival (OS) curves and compared them using the log‐rank test. A high SII, NLR, and PLR were correlated with poor OS (*P* = 0.001, *P* = 0.07, and *P* = 0.023, respectively) (Fig [2](#tca12995-fig-0002){ref-type="fig"}a--c).

![Kaplan--Meier overall survival curves according to the (**a**) systemic immune‐inflammation index (SII), (**b**) neutrophil‐lymphocyte ratio (NLR), and (**c**) platelet‐lymphocyte ratio (PLR).](TCA-10-761-g002){#tca12995-fig-0002}

Moreover, we also investigated the prognostic value of the SII separately in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) subgroups. LUAD patients with higher SII values had worse OS (*P* = 0.001) (Fig [3](#tca12995-fig-0003){ref-type="fig"}a); however, the correlation in the LUSC subgroup was not statistically significant (*P* = 0.116) (Fig [3](#tca12995-fig-0003){ref-type="fig"}b).

![Kaplan--Meier overall survival (OS) curves of patients with high and low platelet‐lymphocyte ratios (PLRs) stratified by histological type. OS of patients with (**a**) lung adenocarcinoma (LUAD) and (**b**) lung squamous cell carcinoma (LUSC). SII, systemic immune‐inflammation index.](TCA-10-761-g003){#tca12995-fig-0003}

Univariate and multivariate analyses {#tca12995-sec-0016}
------------------------------------

Univariate analyses demonstrated that age, tumor length, T stage, lymph node metastasis, TNM stage, operation duration, intraoperative blood loss, SII, NLR, and PLR were significant risk factors for poor OS (Table [3](#tca12995-tbl-0003){ref-type="table"}). When conducting multivariate analyses, we used three separate models to avoid multicollinearity. In each test, only one immune‐inflammatory indicator (SII, NLR, or PLR) was included. The results revealed that age (*P* \< 0.001), lymphatic metastasis (*P* = 0.026), TNM stage (*P* \< 0.001), intraoperative blood loss (*P* **=** 0.039), and high SII values (*P* = 0.034) were independently associated with poor OS (Table [4](#tca12995-tbl-0004){ref-type="table"}).

###### 

Univariate analysis of OS in NSCLC patients

  ----------------------------------------------------------------------------------------------------------------------------
                                                   OS                                                           
  ------------------------------------------------ ---------------------------------------------------- ------- --------------
  Gender (male, female)                            0.242                                                0.862   0.673--1.105

  Age (≤60, \> 60 years)                           **0.001** [\*](#tca12995-note-0004){ref-type="fn"}   1.564   1.263--1.937

  Smoking (ever, never)                            0.248                                                1.142   0.911--1.431

  Tumor length (≤ 4, \> 4)                         **0.001** [\*](#tca12995-note-0004){ref-type="fn"}   1.545   1.248--1.913

  Differentiation (well/moderately, poorly)        0.137                                                1.181   0.948--1.471

  T stage (T1/T2, T3/T4)                           **0.001** [\*](#tca12995-note-0004){ref-type="fn"}   1.682   1.344--2.105

  Lymph node metastasis (negative, positive)       **0.001** [\*](#tca12995-note-0004){ref-type="fn"}   2.050   1.623--2.588

  TNM stage (I/II, III)                            **0.001** [\*](#tca12995-note-0004){ref-type="fn"}   2.270   1.834--2.810

  Operation duration (minutes)\                    **0.008** [\*](#tca12995-note-0004){ref-type="fn"}   1.333   1.079--1.647
  (≤ 150, \> 150)                                                                                               

  Intraoperative blood loss (mL) (≤ 150, \> 150)   **0.034** [\*](#tca12995-note-0004){ref-type="fn"}   1.299   1.020--1.655

  SII (\< 419.6, ≥ 419.6)                          **0.001** [\*](#tca12995-note-0004){ref-type="fn"}   1.433   1.157--1.774

  NLR (\< 1.74, ≥ 1.74)                            **0.007** [\*](#tca12995-note-0004){ref-type="fn"}   1.364   1.087--1.710

  PLR (\< 88.7, ≥ 88.7)                            **0.024** [\*](#tca12995-note-0004){ref-type="fn"}   1.337   1.040--1.719
  ----------------------------------------------------------------------------------------------------------------------------

*P* \< 0.05 is considered significant. CI, confidence interval; HR, hazard ratio; NLR, neutrophil‐lymphocyte ratio; NSCLC, non‐small cell lung cancer; OS, overall survival; PLR, platelet‐lymphocyte ratio; SII, systemic immune‐inflammation index; TNM, tumor node metastasis.

###### 

Multivariate analysis of OS in NSCLC patients

  ----------------------------------------------------------------------------------------------------------------------------
                                                   OS                                                           
  ------------------------------------------------ ---------------------------------------------------- ------- --------------
  Age (≤ 60, \> 60 years)                          **0.001** [\*](#tca12995-note-0005){ref-type="fn"}   1.672   1.349--2.071

  Tumor length (≤ 4, \> 4)                         0.217                                                1.155   0.919--1.451

  T stage (T1/T2, T3/T4)                           0.326                                                1.139   0.878--1.479

  Lymph node metastasis (negative, positive)       **0.026** [\*](#tca12995-note-0005){ref-type="fn"}   1.401   1.041--1.885

  TNM stage (I/II, III)                            **0.001** [\*](#tca12995-note-0005){ref-type="fn"}   1.850   1.410--2.428

  Operation duration (minutes)\                    0.340                                                1.109   0.897--1.372
  (≤ 150, \> 150)                                                                                               

  Intraoperative blood loss (mL) (≤ 150, \> 150)   **0.039** [\*](#tca12995-note-0005){ref-type="fn"}   1.291   1.085--1.667

  SII (\< 419.6, ≥ 419.6)                          **0.034** [\*](#tca12995-note-0005){ref-type="fn"}   1.256   1.018--1.551

  NLR (\< 1.74, ≥ 1.74)                            0.119                                                1.202   0.954--1.515

  PLR (\< 87.83, ≥ 87.83)                          0.092                                                1.247   0.965--1.613
  ----------------------------------------------------------------------------------------------------------------------------

*P* \< 0.05 is considered significant. CI, confidence interval; HR, hazard ratio; NLR, neutrophil‐lymphocyte ratio; NSCLC, non‐small‐cell lung cancer; OS, overall survival; PLR, platelet‐lymphocyte ratio; SII, systemic immune‐inflammation index; TNM, tumor node metastasis.

Univariate and multivariate analyses were also conducted in the LUAD and LUSC subgroups. In the LUAD subgroup, univariate analyses showed that gender, age, smoking history, tumor length, tumor differentiation, T stage, lymph node metastasis, TNM stage, SII, NLR, and PLR were significant risk factors for poor OS (Table S1). The results of multivariate analyses revealed that age (*P* \< 0.001), tumor length (*P* = 0.001), lymphatic metastasis (*P* \< 0.001), high SII values (*P* = 0.014), and high NLR values (*P* = 0.003) were independently associated with poor OS (Table S2). In the LUSC subgroup, the results of univariate analyses showed that tumor differentiation, T stage, lymph node metastasis, TNM stage, and operation duration were significant risk factors for poor OS (Table S3). Multivariate analyses revealed that tumor differentiation (*P* = 0.032) and TNM stage (*P* = 0.023) were independently associated with poor OS (Table S4).

Discussion {#tca12995-sec-0017}
==========

To the best of our knowledge, compared to previous studies, our sample included the largest sample of NSCLC patients. Our study focused exclusively on the prognostic value of the SII in patients with surgically resected NSCLC. We found that the SII was associated with gender, histological type, tumor length, T stage, TNM stage, NLR, and PLR. Furthermore, the preoperative SII was an independent prognostic biomarker for OS in patients with surgically resected NSCLC, and it retained prognostic significance in the LUAD subgroup. Comparison of the AUCs showed that the prognostic ability of the SII was superior to the NLR and PLR.

Cancer‐related inflammation is influential in the tumor microenvironment, and inflammatory cells in the circulation may also play important roles in tumor progression.[21](#tca12995-bib-0021){ref-type="ref"} In recent years a growing body of evidence has revealed that systemic inflammation is correlated with cancer development.[22](#tca12995-bib-0022){ref-type="ref"} Systemic inflammatory responses could induce tumor behavior and are associated with poor clinical outcomes in patients with various types of solid tumors.[23](#tca12995-bib-0023){ref-type="ref"}, [24](#tca12995-bib-0024){ref-type="ref"}, [25](#tca12995-bib-0025){ref-type="ref"}, [26](#tca12995-bib-0026){ref-type="ref"} The NLR and the PLR are two systemic inflammatory indicators; high NLR and PLR values correlate with a poor prognosis.[6](#tca12995-bib-0006){ref-type="ref"}, [9](#tca12995-bib-0009){ref-type="ref"}, [11](#tca12995-bib-0011){ref-type="ref"}, [12](#tca12995-bib-0012){ref-type="ref"}, [27](#tca12995-bib-0027){ref-type="ref"} However, these two inflammatory indicators only integrate two cell types. The SII, which is based on neutrophils, platelets, and lymphocytes, seems to be a stronger prognostic predictor in a variety of solid tumors,[10](#tca12995-bib-0010){ref-type="ref"}, [13](#tca12995-bib-0013){ref-type="ref"}, [14](#tca12995-bib-0014){ref-type="ref"} including NSCLC.[17](#tca12995-bib-0017){ref-type="ref"}, [18](#tca12995-bib-0018){ref-type="ref"}, [19](#tca12995-bib-0019){ref-type="ref"}

The mechanism by which a high SII value contributes to poor survival for cancer patients remains unclear. Several theories have been proposed to explain this phenomenon. Neutrophils can activate both endothelial and parenchymal cells to enhance circulating tumor cell adhesion, promoting distant metastasis.[28](#tca12995-bib-0028){ref-type="ref"} Meanwhile, circulating vascular endothelial growth factor is contained in granulocytes, particularly in neutrophils, which could be important for tumor angiogenesis.[29](#tca12995-bib-0029){ref-type="ref"} Platelets can act as protective "cloaks" to shield circulating tumor cells from immune destruction, induce epithelial‐mesenchymal transition, and promote distant metastasis of tumor cells.[30](#tca12995-bib-0030){ref-type="ref"} Lymphocytes play an important role in immune surveillance and immune defence.[31](#tca12995-bib-0031){ref-type="ref"} Meanwhile, a high density of tumor‐infiltrating lymphocytes is associated with better clinical outcomes in solid tumors, and tumor‐infiltrating lymphocytes are correlated with lymphocytes circulating in the peripheral blood.[32](#tca12995-bib-0032){ref-type="ref"}, [33](#tca12995-bib-0033){ref-type="ref"} Based on this information, a higher SII may be associated with tumor angiogenesis, invasion, and metastasis, thus leading to poor survival. Therefore, an elevated SII is correlated with poor survival in cancer patients.

The results of our study should be interpreted with caution. Our study was a single center retrospective study, thus selection bias was inevitable. Collaborative, multicenter, prospective studies are warranted to confirm our results.

The SII is an independent prognostic predictor in patients with surgically resected NSCLC, and the SII retained prognostic significance in the LUAD subgroup. The SII showed better prognostic ability than the NLR and PLR.
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